Cargando…
Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities
In light of the disappointing termination of clinical trials with potent complex I inhibitors, such as IACS-010759, justification for oxidative phosphorylation inhibitors and mitochondrial targeting strategies has been called into question. Consideration of these agents’ potency, tissue selectivity...
Autores principales: | Machado, Nicole D., Heather, Lisa C., Harris, Adrian L., Higgins, Geoff S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491675/ https://www.ncbi.nlm.nih.gov/pubmed/37563220 http://dx.doi.org/10.1038/s41416-023-02394-9 |
Ejemplares similares
-
HIV-1 Membrane Fusion: Targets of Opportunity
por: Doms, Robert W., et al.
Publicado: (2000) -
The advantages of metalenses over diffractive lenses
por: Engelberg, Jacob, et al.
Publicado: (2020) -
COVID-19 vaccines: neutralizing antibodies and the alum advantage
por: Hotez, Peter J., et al.
Publicado: (2020) -
Is electrosynthesis always green and advantageous compared to traditional methods?
por: Yuan, Yong, et al.
Publicado: (2020) -
MitoTam-01 Trial: Mitochondrial Targeting as Plausible Approach to Cancer Therapy. Comment on Yap et al. Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials. Nat. Med. 2023, 29, 115–126
por: Neuzil, Jiri, et al.
Publicado: (2023)